contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

NeoDynamics

Anna Eriksrud announces desire to retire as CEO of NeoDynamics.Anna Eriksrud, CEO joined NeoDynamics in 2016 and led the company from the start-up phase through to FDA clearance of NeoNavia ...

<div class="mfn-preamble"><p><strong>Anna Eriksrud announces desire to retire as CEO of NeoDynamics.</strong></p></div><div class="mfn-body"><p>Anna Eriksrud, CEO joined NeoDynamics in 2016 and led the company from the start-up phase through to FDA clearance of NeoNavia ® and commercial launch in Europe and the US.</p><p>&nbsp;“Well into my sixties, it is time for me to consider my next chapter and prepare for an orderly management transition at NeoDynamics. When I joined NeoDynamics in 2016, I was hired to bring the company forward to commercial proof of concept, including establishing a network of KOL ambassadors at leading hospitals, and we’re now very close to attaining these important milestones. I am proud of the results we have achieved, and not least the 2022 FDA clearance in the US.” says Anna Eriksrud, CEO, NeoDynamics. </p><p>Ingrid Salén, Chairman comments: “We are grateful to Anna for having safely navigated NeoDynamics through turbulent times. The Covid 19 pandemic, changing ownership structures and finetuning products have made the already challenging certification process and finding key stake holders even more difficult. Anna has taken on these many challenges with much energy and a clear vision. NeoDynamics is now well positioned to leverage our technology and achieve commercial success.&nbsp;Anna will remain until a new CEO is in place to ensure a smooth transition and will have an advisory role through 2024.”</p><p><strong>For further information, please contact:</strong><br>Ingrid Salén, Chairman NeoDynamics AB, phone +46 657 1515 or e-mail <a rel="noopener" href="mailto:Ingrid.salen@rentability.se">Ingrid.salen@rentability.se</a><br>Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444&nbsp;966 or e-mail <a rel="noopener" href="mailto:anna.eriksrud@neodynamics.com">anna.eriksrud@neodynamics.com</a></p></div><div class="mfn-footer mfn-about mfn-67d0674826f8"><p><strong class="mfn-heading-1">About NeoDynamics</strong><br>NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis&nbsp;at leading clinics in&nbsp;Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.</p></div><div class="mfn-footer mfn-2d817adef89e"><p><strong class="mfn-heading-1">About NeoNavia</strong><br>NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.</p></div><div class="mfn-footer mfn-53aa4de9759f"><p><strong class="mfn-heading-1">About Karolinska Institute</strong><br>The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/f4727fed-9514-443e-8a18-3b9353a1d9ea/update-on-neodynamics-management-team.pdf" class="mfn-generated mfn-primary">Update on NeoDynamics’ Management Team</a></p></div>

Update on NeoDynamics’ Management Team

Taloustieteen filosofiaa, osa 7: Seneca, tuo oman aikansa vapaaherra

Vaihteleva viikko takana, isku Iraniin voi viedä mustan kullan hinnan uusiin ulottuvuuksiin

Miksi pörssikurssit nousevat kauppapoliittisesta epävarmuudesta huolimatta?

Kuuluisassa korkosäännössä rahapolitiikka olisi selvästi kiristävämpää

USA:n inflaatio: Pahimmat painajaiset peikosta poistuivat